APA (7th ed.) Citation

M, S., F, G., E, J., P, G., D, K., B, P., . . . P, J. (2021). Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer research, 81(23), 6029. https://doi.org/10.1158/0008-5472.CAN-21-1023

Chicago Style (17th ed.) Citation

M, Szydłowski, et al. "Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies." Cancer Research 81, no. 23 (2021): 6029. https://doi.org/10.1158/0008-5472.CAN-21-1023.

MLA (9th ed.) Citation

M, Szydłowski, et al. "Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies." Cancer Research, vol. 81, no. 23, 2021, p. 6029, https://doi.org/10.1158/0008-5472.CAN-21-1023.